A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.
Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.
A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.
A fully human BCMA-directed CAR-T product showed clinical activity in patients with relapsed/refractory multiple myeloma.
A CAR-T therapy that targets B-cell maturation antigen showed clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma.
Dr Samur and colleagues found that high-dose melphalan caused an approximately 2.5-fold greater mutation accumulation rate than that observed with RVD treatment alone.